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From the Clinic
Nephrotic syndrome in acute promyelocytic leukemia
A five-year-old boy presented (Day 0) with gingival bleed-
ing and pancytopenia (white blood cells: 1.7 × 109/L;
hemoglobin: 7.3 g/dL; platelets: 16 × 109/L). A coagulation
panel was unremarkable. Peripheral blood smear revealed
dysmorphic promyelocytes with red-blue granules, folded
reniform nuclei and no Auer rods. Bone marrow examin-
ation showed immature myeloid cells (>60% promyelo-
cytes) that were positive for myeloperoxidase (MPO),
CD117, CD13 and CD33, and negative for CD34 and HLA-
DR. Cytogenetic analysis showed a male karyotype with
46,XY, t(15;17)(q24;q21). Quantitative real-time polymer-
ase chain reaction was positive for PML-RARα. A diagnosis
of acute promyelocytic leukemia (APL) was established.
Induction chemotherapy with daunorubicin (50 mg/m2
Days 1, 3 and 5), cytarabine (100 mg/m2 every 12 h, Days
1–10) and thioguanine (100 mg/m2 every 12 h, Days 1–10)
along with all-trans retinoic acid (ATRA; 45 mg/m2 per day
in two divided doses starting on Day 1) was initiated on
admission Day 2. Prophylactic dexamethasone (0.1 mg/kg
twice daily) was administered along with ATRA. On Day 9,
the patient developed a hypertensive crisis, bilateral lower
extremity edema, proteinuria (24-h urine protein 1000
mg) and hyperlipidemia (triglycerides: 525 mg/dL, total
cholesterol: 275 mg/dL). His serum albumin at this timewas
3.2 g/dL. Given the above presentation and the definition
of nephrotic-range proteinuria in children (>40 mg/m2/h), a
diagnosis of nephrotic syndrome (NS) (most likely minimal
change disease) was established and steroids (prednisone
2 mg/kg/day) were initiated. Proteinuria and other
manifestations of NS resolved on admission Day 26, after
which steroids were quickly tapered and eventually discon-
tinued. The patient has now completed the second course
of DAT without signs or symptoms of NS. During the second
course, he only received prophylactic doses of steroids.
The association of NS with acute myeloid leukemia
(AML) is rare, with only 10 cases reported previously
(Table 1). There was a remarkable male predominance
(80%), and the median age at diagnosis was 33 (range: 3–
81) years. Surprisingly, 45% of all cases and all three pedi-
atric cases were APL. NS was present before treatment in
45% of cases, suggesting a direct pathogenic role of leu-
kemia. In other cases, anthracycline therapy was the main
culprit. Histopathological findings on renal biopsy did not
reveal a unique pattern and varied from minimal change
disease (MCD) to focal segmental glomerulosclerosis
(FSGS), immune complex deposition, macrophage infiltra-
tion, membranous glomerulonephritis, proliferative glom-
erulonephritis and detachment of epithelial cells from the
glomerular basement membrane. From the nine patients
who received some form of treatment for NS, steroids
were the chosen treatment in seven patients, with a re-
sponse rate of 86%; the other two patients were treated
only with chemotherapy and NS responded to treatment
in both.
A number of mechanisms may explain the rare associ-
ation between NS and AML. Disruption of podocyte integrity
Table 1. Summary of previous reports on the association between AML and NS
Reference,
year
Age, sex,
FAB Induction regimen
Proteinuria
before AML
treatment
Possible
etiology Renal histology
Tx of NS,
response Outcome
[10], 1972 20, M, n/a None + AML Membranous GN None Death at 6 days
(renal failure)
[9], 1983 57, M, M4 Vincristine and prednisone, followed
by cytarabine, daunorubicin, thioguanine,
and prednisone
+ AML FSGS, immune
complex deposits
Steroids
+
CR, relapse at
2 m and death
[11], 1986 81, F, M3 None + n/a Proliferative GN Steroids
–
Early death
[12], 1989 33, M, M2 Cytarabine, daunorubicin – Anthracycline MCD, IgM deposits Steroids
+
Death at 26
days (sepsis)
[13], 1995 33, F, M3 Cytarabine, daunorubicin, 6-MP, prednisone – Anthracycline Epithelial-GBM
detachment
None Death at 16
days (DAH)
[14], 1996 59, M, M2 Enocitabine, daunorubicin, 6-MP,
cytarabine, vincristine, prednisolone, M-CSF
+ M-CSF Macrophage
infiltration
Steroids
+
Death at 14
months (sepsis)
[2], 2002 44, F, M5 Etoposide, cytarabine, daunorubicin + AML n/a, possible MCD ChemoTx
+
Death at
6 months
(DAH)
[15], 2004 53, M, n/a Cytarabine, daunorubicin + AML Membranous GN Steroids
+
n/a
[16], 2010 9, M, M3 Cytarabine, idarubicin, etoposide, ATRA – Anthracycline FSGS Steroids
+
CR at 2 years
[1], 2012 3, M, M3 Cytarabine, daunorubicin, ATRA – ATRA
syndrome
n/a ChemoTx
+
CR
Our case 5, M, M3 Cytarabine, daunorubicin, thioguanine,
ATRA, and dexamethasone
– Anthracycline n/a Steroids
+
CR
6MP, 6-mercaptopurine; AML, acute myeloid leukemia; ATRA, all-trans retinoic acid; ChemoTx, chemotherapy; CR, complete remission; DAH, diffuse
alveolar hemorrhage; FSGS, focal segmental glomerulosclerosis; GBM, glomerular basement membrane; GN, glomerulonephritis; M-CSF, macrophage
colony-stimulating factor; MCD, minimal change disease; n/a, not available; NS, nephrotic syndrome; Tx, treatment.
© The Author 2014. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
For permissions, please email: journals.permissions@oup.com.
Clin Kidney J (2014) 0: 1–2
D
ow
nloaded from
 https://academ
ic.oup.com
/ckj/article-abstract/7/4/424/777852 by W
ashington U
niversity, Law
 School Library user on 16 N
ovem
ber 2019
and function due to cytokine release has been proposed as
a mechanism of nephrotic syndrome during ATRA-induced
differentiation syndrome in APL [1]. A causal relationship
between NS and AML is further supported by the response
of proteinuria to chemotherapy for AML and the association
between higher leukemia burden and more proteinuria
[1, 2]. Anthracyclines have been proposed as a culprit in the
development of NS following treatment of AML since they
can cause acute renal tubulointerstitial toxicity [3, 4]. Also,
adriamycin rapidly increases the expression of the ligands
on podocytes for advanced glycation end products, leading
to podocyte stress and glomerulosclerosis in mouse
models [5]. Adriamycin is now often used to induce experi-
mental FSGS [6, 7]. Finally, NS in AML may reflect a local
immune complex-mediated process [8, 9]. Given the
absence of proteinuria before AML treatment in our patient,
we believe daunorubicin was the most likely cause of NS in
the present case. However, a direct effect of ATRA (e.g. ter-
minal differentiation of promyelocytes and toxic effects of
the released granules) cannot be ruled out. He had no signs
of recurrent NS after re-exposure to chemotherapy, suggest-
ing re-challengemay be safe in drug-induced NS.
Conflict of interest statement. None declared.
1Department of Pediatric
Hematology and Oncology, Besat
Hospital, Kurdistan University of
Medical Sciences and Health
Services, Sanandaj, Iran
2Division of Oncology, Washington
University School of Medicine,
St. Louis, MO, US
3Pediatric Congenital Hematologic
Disorders Research Center, Shahid
Beheshti University of Medical
Sciences, Tehran, Iran
4Department of Pediatric
Nephrology, Besat Hospital,
Kurdistan University of Medical
Sciences and Health Services,
Sanandaj, Iran
Borhan Moradveisi1
Armin Rashidi2
Samin Alavi3
Alireza Eskandarifar4
Correspondence and offprint requests to: Armin Rashidi;
E-mail: arashidi@dom.wustl.edu
References
1. Sethna CB, Reddy K, Fein-Levy C et al. Nephrotic-range pro-
teinuria in a child with retinoic acid syndrome. Pediatr Nephrol
2012; 27: 485–488
2. Levi I, Dinour D, Ben-Bassat I et al. Acute myeloid leukemia
associated with nephrotic syndrome: case report and litera-
ture review. Leuk Lymphoma 2002; 43: 1133–1136
3. Bárdi E, Bobok I, V Oláh A et al. Anthracycline antibiotics
induce acute renal tubular toxicity in children with cancer.
Pathol Oncol Res 2007; 13: 249–253
4. Bertani T, Cutillo F, Zoja C et al. Tubulo-interstitial lesions
mediate renal damage in adriamycin glomerulopathy. Kidney
Int 1986; 30: 488–496
5. Guo J, Ananthakrishnan R, Qu W et al. RAGE mediates podo-
cyte injury in adriamycin-induced glomerulosclerosis. J Am
Soc Nephrol 2008; 19: 961–972
6. Wang Y, Wang YP, Tay YC et al. Progressive adriamycin nephro-
pathy in mice: sequence of histologic and immunohistochem-
ical events. Kidney Int 2000; 58: 1797–1804
7. Chen A, Sheu LF, Ho YS et al. Experimental focal segmental
glomerulosclerosis in mice. Nephron 1998; 78: 440–452
8. Sutherland JC, Mardiney MR Jr. Immune complex disease in the
kidneys of lymphoma-leukemia patients: the presence of an on-
cornavirus-related antigen. J Natl Cancer Inst 1973; 50: 633–644
9. Dosa S, Phillips TM, Antonovych TTet al. Acute myelomonocy-
tic leukemia associated with nephrotic syndrome. A case
report with immunological studies. Nephron 1983; 34:
125–129
10. Agarwal RG, Gupta KD, Bharadwaj TP. Nephrotic syndrome
in the possible terminal blast-cell crisis in myeloid leukaemia
(a case report). J Assoc Physicians India 1972; 20: 799–801
11. Fujita N, Sawada S, Nakanishi S et al. A case of acute promye-
locytic leukemia complicated by nephrotic syndrome. Rinsho
Ketsueki 1986; 27: 1383–1387
12. Thomson M, de Arriba G, Ordi J et al. Acute myelogenous leu-
kemia treated with daunomycin associated with nephrotic
syndrome. Nephron 1989; 51: 261–264
13. Morino N, Nojima Y, Mimura T et al. Nephrotic syndrome de-
veloped in a patient with acute promyelocytic leukemia
treated with daunomycin. Nephron 1995; 70: 374–375
14. Omura K, Kawamura T, Utsunomiya Y et al. Development of
nephrotic syndrome in a patient with acute myeloblastic leu-
kemia after treatment with macrophage-colony-stimulating
factor. Am J Kidney Dis 1996; 27: 883–887
15. Sahiner S, Ayli MD, Yüksel C et al. Membranous nephropathy
associated with acute myeloid leukemia. Transplant Proc
2004; 36: 2618–2619
16. Bariş S, Ozdil M, Topal N et al. Acute promyelocytic leukemia
treated with idarubicin complicated by focal segmental
glomerulosclerosis. J Pediatr Hematol Oncol 2010; 32:
82–84
Received for publication: 14.4.14; Accepted in revised form:
28.5.14
doi: 10.1093/ckj/sfu062
2 B. Moradveisi et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/ckj/article-abstract/7/4/424/777852 by W
ashington U
niversity, Law
 School Library user on 16 N
ovem
ber 2019
